OncoCyte Investor Relations Material
Latest events
Q4 2023
OncoCyte
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from OncoCyte Corporation
Access all reports
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. Its tests apply genetic analysis technology to advance early detection of cancer. The company's lead product candidates are Circulating Tumor Cell (CTC), a blood test to detect lung cancer; and DetermaIO, a bioinformatic analysis software that provides interpretative information on the outputs from various types of assays, including CTC. It is also developing DetermaVu, a cell free DNA blood test for detecting various types of lung cancer; DetermaSolver, a proprietary technology.
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States